Evidence map›Paper›PMID 30501640›Full record

ArticleInfectious diseases of poverty2018

Epidemiology of onchocerciasis-associated epilepsy in the Mbam and Sanaga river valleys of Cameroon: impact of more than 13 years of ivermectin.

Joseph Nelson Siewe Fodjo, Godwin Tatah, Earnest Njih Tabah, Leonard Ngarka, Leonard Njamnshi Nfor, Samuel Eric Chokote, Michel K Mengnjo, Fidèle Dema, Aurélien Tele Sitouok, Grace Nkoro and 6 more

Open access · goldAbstract read
In one paragraph

Article in Infectious diseases of poverty, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. The role of neuromodulation in the management of drug-resistant epilepsy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Joseph Nelson Siewe FodjoGlobal Health Institute, University of Antwerp, Antwerp, Belgium.
Godwin TatahNeurology Department, Yaoundé Central Hospital, Yaoundé, Cameroon.
Earnest Njih TabahNeurology Department, Yaoundé Central Hospital, Yaoundé, Cameroon.
Leonard NgarkaNeurology Department, Yaoundé Central Hospital, Yaoundé, Cameroon.
Leonard Njamnshi NforNeuroscience Laboratory, FMBS, The University of Yaoundé I, Yaoundé, Cameroon.
Samuel Eric ChokoteNeurology Department, Yaoundé Central Hospital, Yaoundé, Cameroon.
Michel K MengnjoNeurology Department, Yaoundé Central Hospital, Yaoundé, Cameroon.
Fidèle DemaNeurology Department, Yaoundé Central Hospital, Yaoundé, Cameroon.
Aurélien Tele SitouokNeurology Department, Yaoundé Central Hospital, Yaoundé, Cameroon.
Grace NkoroNeuroscience Laboratory, FMBS, The University of Yaoundé I, Yaoundé, Cameroon.
Félicien E NtoneNeuroscience Laboratory, FMBS, The University of Yaoundé I, Yaoundé, Cameroon.
Anne-Cécile Zoung-Kanyi BissekNeuroscience Laboratory, FMBS, The University of Yaoundé I, Yaoundé, Cameroon.
Cédric B ChesnaisUMI 233, Institut de Recherche pour le Développement (IRD), Montpellier, France.
Michel BoussinesqUMI 233, Institut de Recherche pour le Développement (IRD), Montpellier, France.
Robert ColebundersGlobal Health Institute, University of Antwerp, Antwerp, Belgium. robert.colebunders@uantwerpen.be.ORCID http://orcid.org/0000-0002-1919-1340
Alfred K NjamnshiNeurology Department, Yaoundé Central Hospital, Yaoundé, Cameroon.
Université de Yaoundé I · CMCentral Hospital of Yaoundé · CMInserm · FRUniversity of Antwerp · BE

Funding

European Research Council 768815
6 · The paper itself

Abstract

backgroundA high epilepsy prevalence has been reported in several onchocerciasis-endemic villages along the Mbam and Sanaga river valleys in Cameroon, including Bilomo and Kelleng. We sought to determine the prevalence of epilepsy in these two villages following more than 13 years of community-directed treatment with ivermectin (CDTI).

methodsDoor-to-door surveys were performed on the entire resident population in the villages in August 2017 and January 2018. Epilepsy was diagnosed using a 2-step approach: administration of a standardized 5-item questionnaire followed by confirmation by a neurologist. Previously published diagnostic criteria for onchocerciasis-associated epilepsy (OAE) were used. Ov16 serology was done for children aged 7-10 years to assess onchocerciasis transmission. Findings were compared with previous data from these two villages.

resultsA total of 1525 individuals (1321 in Bilomo and 204 in Kelleng) in 233 households were surveyed in both villages. The crude prevalence of epilepsy was 4.6% in Bilomo (2017) and 7.8% in Kelleng (2018), including 12 (15.6% of cases) persons with epilepsy (PWE) with nodding seizures. The age and sex-standardized prevalence in Kelleng decreased from 13.5% in 2004 to 9.3% in 2018 (P < 0.001). The median age of PWE shifted from 17 (IQR: 12-22) years to 24 (IQR: 20-30) years in Bilomo (P < 0.001); and slightly from 24 (IQR: 14-34) years to 28 (IQR: 21.25-36.75) years in Kelleng (P = 0.112). Furthermore, 47.6% of all tested children between 7 and 10 years had Ov16 antibodies.

conclusionsThere is a decrease in epilepsy prevalence after 13 years and more of CDTI in both villages. The age-shift observed in PWE suggests that ivermectin may prevent OAE in younger residents. Ov16 seropositivity in children indicates ongoing onchocerciasis transmission possibly due to suboptimal control measures. Our findings support the existence of OAE in Cameroon and highlight the need to strengthen onchocerciasis elimination programs.

Indexed as

RiversAdolescentAdultAntiparasitic AgentsCameroonChildChild, PreschoolEpilepsyFemaleHumansInfantIvermectinMaleMiddle AgedOnchocerciasisPrevalenceAntiparasitic AgentsIvermectinCameroonEpilepsyIvermectinNodding syndromeOnchocerciasisOv16 rapid diagnostic test

Identifiers

PMID30501640
PMCPMC6276171
OpenAlexW2898977341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.